WebNews
Please enter a web search for web results.
NewsWeb
Hanchor Bio Tests Broader Ambitions for HCB101 Through Inx Med Partnership
9+ hour, 15+ min ago (417+ words) FBD Biologics, a subsidiary of Hanchor Bio, has signed a strategic memorandum of understanding (MOU) with Inx Med. Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist Inx…...
Contributor: Medicare's new approach to halting fraud is paying off
21+ min ago (951+ words) Last year, we wrote in the Los Angeles Times that the Centers for Medicare and Medicaid Services was done chasing criminals after we'd already handed them money. We said we were building something different " a prevention-first operation that would detect…...
John Muir - Chief Medical Information Officer
1+ hour, 59+ min ago (68+ words) Startup Hub. ai John Muir is the Chief Medical Information Officer at Providence, a leading healthcare organization. He is responsible for overseeing the organization's medical information systems and driving digital transformation in healthcare delivery. John Muir is currently Chief Medical…...
How Dev Technosys CEO Tarun Nagar Is Transforming Healthcare Software Development in 2026
2+ hour, 49+ min ago (61+ words) open PR. com How Dev Technosys CEO Tarun Nagar Is Transforming Healthcare Software Development in 2026 Press release from: Dev Technosys Permanent link to this press release: You can edit or delete your press release How Dev Technosys CEO Tarun Nagar…...
One Source Specialty Pharma: No Material Impact from DRL Supply Delay; Expands Capacity
1+ hour, 15+ min ago (409+ words) One Source Specialty Pharma reassured investors that a supply delay from partner Dr. Reddy's Laboratories has no material impact. The company highlighted diversified demand and confirmed new manufacturing capacity coming online this quarter. One Source Specialty Pharma has stated that…...
Astra Zeneca Loses KES 3. 3 Trillion in Value After Major Heart Drug Trial Fails
52+ min ago (272+ words) A Phase III trial failure for the ATTR-CM drug Wainua has wiped "20 billion from Astra Zeneca's market capitalization, sending shockwaves through global markets. The failure stems from the CARDIO-TTRansform study, the largest clinical trial ever conducted for ATTR-CM, encompassing 1, 432 patients…...
In Conversation with Eric Tse, Heir to One of China's Leading Pharmaceutical Groups, on Lessons from SBP Group's 20-Year Path to Global Success
59+ min ago (722+ words) July 9, 2026 | By Techsauce Team Eric Tse defines the company's identity as pioneer innovation, or being an innovation pioneer rather than a follower. But that was only the beginning. The next goal Eric is pushing the organization toward is to move…...
Novo Nordisk India Exec Says AWIQLI Of 2100 Units Is Priced At 7833 Rupees
1+ hour, 50+ min ago (33+ words) Trading View Novo Nordisk India Exec Says AWIQLI Of 2100 Units Is Priced At 7833 Rupees More news from Reuters...
Astra Zeneca shares slide on failure of cardiomyopathy trial
1+ hour, 31+ min ago (155+ words) Astra Zeneca said on Thursday that the phase 3 CARDIO-TTRansform trial of Wainua in adults with transthyretin-mediated amyloid cardiomyopathy did not meet its primary endpoint, failing to show a statistically significant benefit against placebo on the composite measure of cardiovascular mortality…...
Astra Zeneca shares slide 9% as Wainua drug fails key heart trial | Ask Traders. com %
1+ hour, 16+ min ago (209+ words) Astra Zeneca lost about "19 billion in market value on Thursday after its Wainua drug missed the main goal of a late-stage heart disease trial. Astra Zeneca (LSE: AZN) shares dipped sharply in early trading on Thursday after the company said…...